Abstract
Ferroptosis is a promising strategy for cancer therapy, with numerous inhibitors of its braking axes under investigation as potential drugs. However, few studies have explored the potential of activating the driving axes to induce ferroptosis. Herein, phosphatidylcholine peroxide decorating liposomes ($LIP_{PCPO}$) are synthesized to induce ferroptosis by targeting divalent metal transporter 1 (DMT1). $LIP_{PCPO}$ is found to boost lysosomal $Fe^{2+}$ efflux by inducing cysteinylation of lysosomal DMT1, resulting in glutathione peroxidase 4 (GPX4) suppression, glutathione depletion and ferroptosis in breast cancer cells and xenografts. Importantly, $LIP_{PCPO}$ induced ferroptotic cell death is independent of acquired resistance to radiation, chemotherapy, or targeted agents in 11 cancer cell lines. Furthermore, a strong synergistic ferroptosis effect is observed between $LIP_{PCPO}$ and an FDA-approved drug, artesunate, as well as X rays. The formula of $LIP_{PCPO}$ encapsulating artesunate significantly inhibits tumor growth and metastasis and improves the survival rate of breast cancer-bearing female mice. These findings provide a distinct strategy for inducing ferroptosis and highlight the potential of $LIP_{PCPO}$ as a vector to synergize the therapeutic effects of conventional ferroptosis inducers.
Introduction
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a potent strategy for treating various cancers. Most current research focuses on inhibiting the "braking axes," such as the GPX4 enzyme, which prevents lipid peroxide accumulation. However, cancer cells frequently develop resistance to these inhibitors. This study addresses the gap in activating the "driving axes" of ferroptosis—processes that actively promote cell death—by developing phosphatidylcholine peroxide decorating liposomes ($LIP_{PCPO}$).
Methods: Synthesis and Screening of $LIP_{PCPO}$
The researchers synthesized a library of 70 nanomaterials, including metallic, carbonaceous, and lipid-based structures, to identify effective ferroptosis inducers. The synthesis of $LIP_{PCPO}$ involved a LOX-mediated process, using lipoxygenase (5-LOX) to create stereospecific peroxide groups on polyunsaturated phospholipids. Molecular dynamics (MD) simulations and proteomics were employed to study the interactions between these liposomes and cellular targets.
Key Insights: Activating the Driving Axis via DMT1
The study revealed that $LIP_{PCPO}$ specifically targets the lysosomal protein Divalent Metal Transporter 1 (DMT1). By inducing cysteinylation of DMT1, the liposomes lock the transporter into an active state, causing a massive efflux of $Fe^{2+}$ from lysosomes into the cytoplasm. This surge in the labile iron pool triggers glutathione (GSH) depletion and GPX4 suppression, leading to runaway lipid peroxidation and ferroptosis.
Results: Overcoming Resistance and Therapeutic Synergy
$LIP_{PCPO}$ demonstrated potent cytotoxicity across 11 cancer cell lines, including those resistant to doxorubicin, cisplatin, and radiation. Notably, the treatment achieved over 80% cell death in doxorubicin-resistant MCF-7R cells. Furthermore, $LIP_{PCPO}$ showed strong synergy with the FDA-approved drug artesunate ($AS$) and X-ray radiation. In vivo studies using breast cancer xenografts showed that the $AS@LIP_{PCPO}$ formula significantly inhibited tumor growth (2.5-fold reduction) and improved survival rates, with 60% of mice surviving beyond 60 days compared to 0% in control groups.
Conclusion
This work introduces a novel strategy for inducing ferroptosis by activating the driving axis of iron metabolism. $LIP_{PCPO}$ serves as a versatile synthetic vector that bypasses common resistance mechanisms and synergizes with existing therapies. Future work will focus on optimizing phospholipid chain lengths and further characterizing the "protein corona" to facilitate clinical translation.
Summary updated